Published in Science on October 03, 1997
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med (2000) 3.00
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A (2004) 2.57
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 2.55
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med (2000) 2.10
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med (2000) 1.83
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol (2001) 1.82
BLyS and APRIL in rheumatoid arthritis. J Clin Invest (2005) 1.75
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest (2007) 1.58
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol (2006) 1.43
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood (2006) 1.35
Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology (2006) 1.30
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
A role for BLyS in the activation of innate immune cells. Blood (2006) 1.27
The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cell lines. Proc Natl Acad Sci U S A (1998) 1.26
CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes (2009) 1.24
The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys (2008) 1.23
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A (2004) 1.21
B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol (2008) 1.21
DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem (2003) 1.20
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
APRIL and BAFF connect autoimmunity and cancer. J Exp Med (2000) 1.11
TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood (2005) 1.09
Selective activation of TACI by syndecan-2. Blood (2005) 1.09
The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency. J Allergy Clin Immunol (2010) 1.08
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood (2005) 1.06
Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med (2013) 1.06
Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci (2008) 1.05
Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci (2004) 1.05
The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function. Blood (2009) 1.04
B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.03
Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency. Clin Exp Immunol (2007) 1.03
TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood (2011) 1.00
Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J Allergy Clin Immunol (2009) 0.98
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch (2005) 0.96
Immediate early gene X-1 interacts with proteins that modulate apoptosis. Biochem Biophys Res Commun (2004) 0.96
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med (2010) 0.94
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood (2008) 0.93
Homeostatic control of B lymphocyte subsets. Immunol Res (2008) 0.92
Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. BMC Mol Biol (2002) 0.92
Non-Canonical NF-κB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front Immunol (2014) 0.91
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia (2010) 0.90
Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation. J Allergy Clin Immunol (2011) 0.90
Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One (2011) 0.88
Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. Clin Immunol (2015) 0.86
Therapeutic effects of TACI-Ig on rat with adjuvant arthritis. Clin Exp Immunol (2010) 0.86
B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response. Arthritis Res (2002) 0.84
RNF122: a novel ubiquitin ligase associated with calcium-modulating cyclophilin ligand. BMC Cell Biol (2010) 0.84
Essential role for CAML in follicular B cell survival and homeostasis. J Immunol (2012) 0.84
TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen. J Clin Invest (2014) 0.83
Conditional deletion of calcium-modulating cyclophilin ligand causes deafness in mice. Mamm Genome (2011) 0.83
Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS). Biol Direct (2011) 0.82
The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol (2014) 0.82
Identification of a novel immunosubversion mechanism mediated by a virologue of the B-lymphocyte receptor TACI. Clin Vaccine Immunol (2007) 0.82
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz) (2008) 0.80
Airway and interstitial lung disease are distinct entities in paediatric common variable immunodeficiency. Clin Exp Immunol (2011) 0.80
Effect of calcium-modulating cyclophilin ligand on human immunodeficiency virus type 1 particle release and cell surface expression of tetherin. J Virol (2009) 0.80
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol (2008) 0.79
B-cell-activating factor is a regulator of adipokines and a possible mediator between adipocytes and macrophages. Exp Mol Med (2013) 0.78
MUC1 mucin interacts with calcium-modulating cyclophilin ligand. Int J Biochem Cell Biol (2008) 0.78
Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PLoS One (2013) 0.78
BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Braz J Med Biol Res (2013) 0.77
Common variable immunodeficiency: two mutations are better than one. J Clin Invest (2013) 0.77
Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res (2011) 0.76
Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PLoS One (2014) 0.76
Cyclophilin B enhances HIV-1 infection. Virology (2016) 0.75
Heterozygosity for transmembrane activator and calcium modulator ligand interactor A144E causes haploinsufficiency and pneumococcal susceptibility in mice. J Allergy Clin Immunol (2016) 0.75
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells. Eur J Immunol (2017) 0.75
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci (2016) 0.75
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature (1991) 6.30
Specific protein binding to far upstream activating sequences in polymerase II promoters. Proc Natl Acad Sci U S A (1985) 4.85
The ribonuclease III site flanking 23S sequences in the 30S ribosomal precursor RNA of E. coli. Cell (1980) 4.19
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
A GAL family of upstream activating sequences in yeast: roles in both induction and repression of transcription. EMBO J (1986) 3.29
Isolation of a Saccharomyces cerevisiae centromere DNA-binding protein, its human homolog, and its possible role as a transcription factor. Mol Cell Biol (1987) 2.96
Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools. J Biol Chem (1998) 1.07
Isolation of mutant T lymphocytes with defects in capacitative calcium entry. Immunity (1995) 1.01
Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome (2000) 0.91
A hydrophobic domain of Ca2+-modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J Biol Chem (1996) 0.91
Calcium-modulating cyclophilin ligand desensitizes hormone-evoked calcium release. Biochem Biophys Res Commun (2000) 0.84
CAML regulates Bim-dependent thymocyte death. Cell Death Differ (2010) 0.82